MITOXANTRONE

SynDRA canonical compound SYN0000304 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	TOP2A
Mechanism of action	Topoisomerase inhibitor
Indication	acute myeloid leukemia (AML) \| multiple sclerosis \| prostate cancer
Disease area	hematologic malignancy \| neurology/psychiatry \| oncology

All known targets

mitoxantrone hydrochloride
dihydroxyanthraquinone
mitoxanthrone
mitozantrone
nimitoxantron
mitoxantrone dihydrochloride
mitoxantrone HCl
Mitoxantrona
Misostol
NSC-279836
DHAD
DHAQ
Dihydroxyanthraquinone
MIX
Mitoxanthrone
Mitoxantron
Mitoxantronum
Mitozantrone
DHAQ HCl
Mitoxantrone [INN]
Mitozantrone hydrochloride
Mitoxantrone 2HCl
Liposome Encapsulated Mitoxantrone (LEM)
Misostol (TN)
Mitoxantrona [INN-Spanish]
Mitoxantrone (INN)
Mitoxantrone (free base)
Mitoxantronum [INN-Latin]
Novantrone (TN)
AN-584/42007670
Novantrone(R) (mitoxantrone for injection concentrate)
DHAQ (*Diacetate salt*)
MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE
MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE
1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE
1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione
1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon